TMPRSS11D

Summary

TMPRSS11D (transmembrane serine protease 11D, HGNC:24059) is a protein-coding gene on chromosome 4q13.2, encoding Transmembrane protease serine 11D (O60235). May play some biological role in the host defense system on the mucous membrane independently of or in cooperation with other substances in airway mucous or bronchial secretions.

This gene encodes a trypsin-like serine protease released from the submucosal serous glands onto mucous membrane. It is a type II integral membrane protein and has 29-38% identity in the sequence of the catalytic region with human hepsin, enteropeptidase, acrosin, and mast cell tryptase. The noncatalytic region has little similarity to other known proteins. This protein may play some biological role in the host defense system on the mucous membrane independently of or in cooperation with other substances in airway mucous or bronchial secretions. This protein facilitates entry of viruses into host cells by proteolytically cleaving and activating viral envelope glycoproteins.

Source: NCBI Gene 9407 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 57 total — 1 likely-pathogenic
• Druggable target: yes
• MANE Select transcript: NM_004262

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24059
Approved symbol	TMPRSS11D
Name	transmembrane serine protease 11D
Location	4q13.2
Locus type	gene with protein product
Status	Approved
Aliases	HAT, ASP
Ensembl gene	ENSG00000153802
Ensembl biotype	protein_coding
OMIM	605369
Entrez	9407

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 4 protein_coding_CDS_not_defined, 2 protein_coding, 2 retained_intron

ENST00000283916, ENST00000502573, ENST00000502822, ENST00000505533, ENST00000508409, ENST00000509584, ENST00000511931, ENST00000514868

RefSeq mRNA: 1 — MANE Select: NM_004262 NM_004262

CCDS: CCDS3518

Canonical transcript exons

ENST00000283916 — 10 exons

Exon	Start	End
ENSE00001228417	67820876	67822498
ENSE00002045096	67883926	67884002
ENSE00003490097	67859557	67859678
ENSE00003535368	67827261	67827520
ENSE00003556113	67833204	67833381
ENSE00003591598	67825732	67825874
ENSE00003602290	67854068	67854186
ENSE00003624208	67838172	67838329
ENSE00003628627	67835083	67835121
ENSE00003687534	67842558	67842625

Expression profiles

Bgee: expression breadth ubiquitous, 168 present calls, max score 99.36.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.3406 / max 116.5213, expressed in 45 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
52318	0.3057	42
52319	0.0348	17

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tongue squamous epithelium	UBERON:0006919	99.36	gold quality
gingiva	UBERON:0001828	99.28	gold quality
gingival epithelium	UBERON:0001949	99.27	gold quality
esophagus squamous epithelium	UBERON:0006920	98.74	gold quality
squamous epithelium	UBERON:0006914	98.56	gold quality
epithelium of esophagus	UBERON:0001976	97.95	gold quality
cervix epithelium	UBERON:0004801	97.59	gold quality
lower esophagus mucosa	UBERON:0035834	96.93	gold quality
oral cavity	UBERON:0000167	96.39	gold quality
cervix squamous epithelium	UBERON:0006922	96.26	gold quality
esophagus mucosa	UBERON:0002469	96.10	gold quality
body of tongue	UBERON:0011876	94.71	gold quality
amniotic fluid	UBERON:0000173	94.55	gold quality
pharyngeal mucosa	UBERON:0000355	94.34	gold quality
buccal mucosa cell	CL:0002336	94.26	gold quality
periodontal ligament	UBERON:0008266	91.73	gold quality
penis	UBERON:0000989	91.17	gold quality
tongue	UBERON:0001723	90.50	gold quality
palpebral conjunctiva	UBERON:0001812	90.04	gold quality
mammalian vulva	UBERON:0000997	89.39	gold quality
vagina	UBERON:0000996	88.39	gold quality
sperm	CL:0000019	87.33	gold quality
male germ cell	CL:0000015	86.86	gold quality
nasal cavity epithelium	UBERON:0005384	86.22	silver quality
olfactory segment of nasal mucosa	UBERON:0005386	85.88	gold quality
epithelium of nasopharynx	UBERON:0001951	84.01	gold quality
nasopharynx	UBERON:0001728	83.99	gold quality
superior surface of tongue	UBERON:0007371	83.69	gold quality
nasal cavity mucosa	UBERON:0001826	81.56	gold quality
pancreatic ductal cell	CL:0002079	81.54	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ATF2, NR5A1, TFAP2A

miRNA regulators (miRDB)

81 targeting TMPRSS11D, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-6888-3P	99.97	65.95	1170
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-300	99.92	71.76	2856

Literature-anchored findings (GeneRIF, showing 19)

• HAT regulates cellular functions of human bronchial epithelial cells via activation of protease-activated receptor-2. (PMID:12630574)
• HAT might promote PAR-2-mediated IL-8 production to accumulate inflammatory cells in the epidermal layer of psoriasis. (PMID:15102084)
• results indicate that HAT stimulates fibroblast proliferation in bronchial airways through a PAR-2-dependent MEK-MAPK mediated pathway and that HAT is linked to airway processes involving fibroblasts (PMID:16199437)
• HAT induces amphiregulin production through the PAR-2 mediated ERK pathway, and then causes amphiregulin release by a TACE-dependent mechanism (PMID:16336275)
• TMPRSS2 and HAT are candidates for proteolytic activation of influenza viruses in vivo (PMID:16973594)
• Human HAT cleaved severe acute respiratory syndrome coronavirus spike protein at R667, as determined by mutagenesis and mass spectrometry. (PMID:21994442)
• results suggest that HAI-1 functions as a physiological regulator of HAT by inhibiting its protease activity and proteolytic activation in airway epithelium.(HAT) (PMID:22023801)
• HAT cleaves proMSP at the physiological activation site (PMID:22245154)
• TMPRSS2 and HAT are expressed by important influenza and SARS-coronavirus target cells and could thus support viral spread in the human host. (PMID:22558251)
• H9N2 viruses with R-S-S-R or R-S-R-R cleavage sites in hemagglutinin are activated by matriptase in addition to HAT and TMPRSS2 and, therefore, can be activated in a wide range of tissues what may affect virus spread, tissue tropism and pathogenicity. (PMID:23192872)
• HAT expression may potentially be useful as a marker for clinical grading and assessment of patient prognosis in squamous cell carcinomas (PMID:26297835)
• we conclude that TMPRSS11D could play a role in non-small cell lung cancer development and progression (PMID:28086212)
• High HAT expression is associated with Idiopathic pulmonary fibrosis. (PMID:29122847)
• HAT concentration in saliva was measured by ELISA, and immunoreactive HAT:total protein ratio (ng/mg) in saliva samples from healthy subjects was similar to that in mucoid sputum. RT-PCR showed that HAT mRNA was expressed in gingival epithelial cells but not in gingival fibroblasts. (PMID:30282870)
• serine proteases transmembrane protein serine 11D and kallikrein-related peptidase 13 were shown as active proteases in Cervical-vaginal fluid. (PMID:30647911)
• results indicate that HAT stimulates IL-8 synthesis in airway epithelial cells via PAR2 and could help to amplify inflammation in chronic respiratory tract disease (PMID:30677406)
• TMPRSS11D and TMPRSS13 Activate the SARS-CoV-2 Spike Protein. (PMID:33671076)
• HalphaT is associated with increased risk for severe Hymenoptera venom-triggered anaphylaxis. (PMID:36529562)
• TMPRSS11D/ALR-mediated ER stress regulates the function of myeloid-derived suppressor cells in the cervical cancer microenvironment. (PMID:37666068)

Cross-species orthologs

10 orthologs

Organism	Symbol	Gene ID
danio_rerio	st14b	ENSDARG00000044655
danio_rerio	st14a	ENSDARG00000061173
danio_rerio		ENSDARG00000062758
danio_rerio	tmprss15	ENSDARG00000079393
mus_musculus	Tmprss11d	ENSMUSG00000061259
rattus_norvegicus	Tmprss11d	ENSRNOG00000055991
drosophila_melanogaster	Sb	FBGN0003319
drosophila_melanogaster	CG1632	FBGN0030027
drosophila_melanogaster	CG10587	FBGN0037039
drosophila_melanogaster	CG17242	FBGN0250841

Paralogs (17): PRSS22 (ENSG00000005001), PRSS21 (ENSG00000007038), TMPRSS11E (ENSG00000087128), HPN (ENSG00000105707), TMPRSS13 (ENSG00000137747), ST14 (ENSG00000149418), TMPRSS15 (ENSG00000154646), TMPRSS3 (ENSG00000160183), TMPRSS5 (ENSG00000166682), TMPRSS7 (ENSG00000176040), TMPRSS9 (ENSG00000178297), TMPRSS2 (ENSG00000184012), TMPRSS11B (ENSG00000185873), TMPRSS6 (ENSG00000187045), TMPRSS11A (ENSG00000187054), TMPRSS11F (ENSG00000198092), PRSS41 (ENSG00000215148)

Protein

Protein identifiers

Transmembrane protease serine 11D — O60235 (reviewed: O60235)

Alternative names: Airway trypsin-like protease

All UniProt accessions (2): O60235, H0Y8K7

UniProt curated annotations — full annotation on UniProt →

Function. May play some biological role in the host defense system on the mucous membrane independently of or in cooperation with other substances in airway mucous or bronchial secretions. Plays a role in the proteolytic processing of ACE2. Proteolytically cleaves and activates the human coronavirus 229E (HCoV-229E) spike glycoprotein which facilitate virus-cell membrane fusions; spike proteins are synthesized and maintained in precursor intermediate folding states and proteolysis permits the refolding and energy release required to create stable virus-cell linkages and membrane coalescence. Preferentially cleaves the C-terminal side of arginine residues at the P1 position of certain peptides, cleaving Boc-Phe-Ser-Arg-4-methylcoumaryl-7-amide most efficiently and having an optimum pH of 8.6 with this substrate.

Subunit / interactions. Monomer.

Subcellular location. Cell membrane Secreted.

Tissue specificity. Located in the cells of the submucosal serous glands of the bronchi and trachea.

Activity regulation. Strongly inhibited by diisopropyl fluorophosphate, leupeptin, antipain, aprotinin, and soybean trypsin inhibitor, but hardly inhibited by secretory leukocyte protease inhibitor at 10 microM.

Similarity. Belongs to the peptidase S1 family.

RefSeq proteins (1): NP_004253* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000082	SEA_dom	Domain
IPR001254	Trypsin_dom	Domain
IPR001314	Peptidase_S1A	Family
IPR009003	Peptidase_S1_PA	Homologous_superfamily
IPR017329	Pept_S1A_HAT/DESC1	Family
IPR018114	TRYPSIN_HIS	Active_site
IPR033116	TRYPSIN_SER	Active_site
IPR036364	SEA_dom_sf	Homologous_superfamily
IPR043504

Pfam: PF00089, PF01390

Enzyme classification (BRENDA):

• EC 3.4.21.B61 — (BRENDA: organisms, substrates, inhibitors, Km, kcat entries)

UniProt features (15 total): disulfide bond 4, active site 3, chain 2, topological domain 2, domain 2, glycosylation site 1, transmembrane region 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
8VIS	X-RAY DIFFRACTION	1.59
9DPF	X-RAY DIFFRACTION	1.9

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O60235-F1	90.42	0.73

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 227 (charge relay system); 272 (charge relay system); 368 (charge relay system)

Disulfide bonds (4): 173–292, 212–228, 337–353, 364–393

Glycosylation sites (1): 144

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 78 (showing top): GOBP_RESPIRATORY_GASEOUS_EXCHANGE_BY_RESPIRATORY_SYSTEM, chr4q13, GOBP_PROTEIN_MATURATION, GROSS_HIF1A_TARGETS_DN, GROSS_HYPOXIA_VIA_HIF1A_DN, MODULE_99, RGAGGAARY_PU1_Q6, TAATTA_CHX10_01, GAL_LEUKEMIC_STEM_CELL_UP, GOBP_PROTEOLYSIS, GOMF_PEPTIDASE_ACTIVITY, MOREAUX_MULTIPLE_MYELOMA_BY_TACI_UP, DODD_NASOPHARYNGEAL_CARCINOMA_DN, YAGI_AML_WITH_T_8_21_TRANSLOCATION, RICKMAN_HEAD_AND_NECK_CANCER_E

GO Biological Process (2): proteolysis (GO:0006508), respiratory gaseous exchange by respiratory system (GO:0007585)

GO Molecular Function (5): serine-type endopeptidase activity (GO:0004252), peptidase activity (GO:0008233), serine-type peptidase activity (GO:0008236), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (4): extracellular region (GO:0005576), plasma membrane (GO:0005886), extracellular exosome (GO:0070062), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
protein metabolic process	1
multicellular organismal process	1
endopeptidase activity	1
serine-type peptidase activity	1
hydrolase activity	1
catalytic activity, acting on a protein	1
peptidase activity	1
serine hydrolase activity	1
binding	1
catalytic activity	1
membrane	1
cell periphery	1
extracellular vesicle	1

Protein interactions and networks

STRING

942 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TMPRSS11D	FURIN	P09958	667
TMPRSS11D	ACE2	Q9BYF1	639
TMPRSS11D	CTSL	P07711	609
TMPRSS11D	CTSS	P25774	544
TMPRSS11D	SERPINA5	P05154	518
TMPRSS11D	GFER	P55789	511
TMPRSS11D	ZBED5	Q49AG3	479
TMPRSS11D	ZBED1	O96006	430
TMPRSS11D	SPINT1	O43278	409
TMPRSS11D	CTSB	P07858	397
TMPRSS11D	IL1RN	P18510	396
TMPRSS11D	ZBED4	O75132	395
TMPRSS11D	IL1A	P01583	394
TMPRSS11D	SCAND3	Q6R2W3	393
TMPRSS11D	DPP4	P27487	392

IntAct

8 interactions, top by confidence:

A	B	Type	Score
SGTA	TMPRSS11D	psi-mi:“MI:0915”(physical association)	0.560
TMPRSS11D	S	psi-mi:“MI:0570”(protein cleavage)	0.440
TMPRSS11D	MST1	psi-mi:“MI:0194”(cleavage reaction)	0.440
SRRT	A2ML1	psi-mi:“MI:0914”(association)	0.350
FNDC5	A2ML1	psi-mi:“MI:0914”(association)	0.350
TMPRSS11D	SGTA	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (8): ACE2 (Biochemical Activity), S (Biochemical Activity), TMPRSS11D (Two-hybrid), TMPRSS11D (Affinity Capture-MS), TMPRSS11D (Affinity Capture-MS), TMPRSS11D (Biochemical Activity), S (Biochemical Activity), TMPRSS11D (Co-crystal Structure)

ESM2 similar proteins: A0A126GUP6, A0A1S4H5M5, A0A1S4H5S2, A6MFK7, B5U2W0, F5HKX0, O60235, O88947, O97366, P00740, P05049, P13582, P15120, P15638, P16292, P16293, P16294, P19540, P21902, P25155, P29598, P49150, P81428, P82807, P83370, P98121, Q14C59, Q27081, Q27083, Q2VG86, Q3UQ41, Q49QW1, Q4QXT9, Q63207, Q6ZMR5, Q7PEV7, Q7QBP4, Q804X6, Q8I6K0, Q8MZM7

Diamond homologs: A0A126GUP6, A0A182C2Z2, A0A1S4H5M5, A8JUP7, B5U2W0, B7YZU2, F5HKX0, O15393, O35453, O60235, O60259, O97366, P00774, P03951, P03952, P05049, P05981, P08419, P09871, P10323, P13582, P14272, P21902, P23578, P25155, P26262, P28175, P29293, P31394, P33587, P35035, P35036, P35037, P35039, P35041, P35045, P35046, P35047, P40313, P48038

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

57 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	47
Likely benign	5
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
635941	Single allele	Likely pathogenic

SpliceAI

1338 predictions. Top by Δscore:

Variant	Effect	Δscore
4:67838168:TTA:T	donor_loss	1.0000
4:67838169:TA:T	donor_loss	1.0000
4:67838170:A:AC	donor_gain	1.0000
4:67838170:ACATG:A	donor_loss	1.0000
4:67838171:C:CA	donor_gain	1.0000
4:67838171:CA:C	donor_gain	1.0000
4:67838171:CAT:C	donor_gain	1.0000
4:67838171:CATG:C	donor_gain	1.0000
4:67838171:CATGT:C	donor_gain	1.0000
4:67838325:CTTGC:C	acceptor_gain	1.0000
4:67838327:TGCC:T	acceptor_loss	1.0000
4:67838328:GCCTG:G	acceptor_loss	1.0000
4:67838330:C:CA	acceptor_loss	1.0000
4:67838330:C:CC	acceptor_gain	1.0000
4:67838338:CA:C	acceptor_gain	1.0000
4:67838339:A:C	acceptor_gain	1.0000
4:67854062:ACTT:A	donor_loss	1.0000
4:67854063:CTT:C	donor_loss	1.0000
4:67854064:TTACC:T	donor_loss	1.0000
4:67854065:TACCA:T	donor_loss	1.0000
4:67854066:A:AC	donor_gain	1.0000
4:67854066:A:T	donor_loss	1.0000
4:67854066:AC:A	donor_gain	1.0000
4:67854067:C:CA	donor_gain	1.0000
4:67854067:CC:C	donor_gain	1.0000
4:67854067:CCA:C	donor_gain	1.0000
4:67854067:CCAG:C	donor_gain	1.0000
4:67854067:CCAGA:C	donor_gain	1.0000
4:67854182:TTGAT:T	acceptor_gain	1.0000
4:67854183:TGAT:T	acceptor_gain	1.0000

AlphaMissense

2728 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:67827280:C:A	W311C	0.996
4:67827280:C:G	W311C	0.996
4:67825817:C:G	C337S	0.995
4:67825818:A:T	C337S	0.995
4:67827393:C:G	A274P	0.992
4:67827398:T:A	D272V	0.992
4:67827398:T:G	D272A	0.992
4:67822430:G:C	S388R	0.991
4:67822430:G:T	S388R	0.991
4:67822432:T:G	S388R	0.991
4:67833296:C:A	W200C	0.991
4:67833296:C:G	W200C	0.991
4:67822361:C:A	W411C	0.990
4:67822361:C:G	W411C	0.990
4:67822427:C:A	W389C	0.990
4:67822427:C:G	W389C	0.990
4:67825769:C:G	C353S	0.990
4:67825770:A:T	C353S	0.990
4:67825817:C:T	C337Y	0.989
4:67833212:G:C	C228W	0.989
4:67822441:C:A	G385W	0.988
4:67827282:A:G	W311R	0.988
4:67827282:A:T	W311R	0.988
4:67827392:G:T	A274E	0.988
4:67827399:C:G	D272H	0.988
4:67822416:C:G	C393S	0.987
4:67822417:A:T	C393S	0.987
4:67827397:G:C	D272E	0.987
4:67827397:G:T	D272E	0.987
4:67833298:A:G	W200R	0.987

dbSNP variants (sampled 300 via entrez): RS1000046730 (4:67857518 G>A), RS1000047283 (4:67827922 T>C), RS1000124363 (4:67870417 A>G), RS1000134446 (4:67844073 T>C,G), RS1000144675 (4:67857032 G>A,C), RS1000179697 (4:67879454 A>C), RS1000242477 (4:67870611 G>A), RS1000262535 (4:67824092 G>T), RS1000276158 (4:67864201 C>A), RS1000284528 (4:67838544 G>A), RS1000329712 (4:67876761 T>C), RS1000393069 (4:67880980 G>A), RS1000440029 (4:67844404 A>G), RS10004555 (4:67867295 C>T), RS1000518427 (4:67851654 C>T)

Disease associations

OMIM: gene MIM:605369 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST004068_32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T	9.000000e-07
GCST006921_13	Regular attendance at a pub or social club	7.000000e-09
GCST009391_1284	Metabolite levels	7.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0009592	social interaction measurement
EFO:0009792	valine measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL1795138 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — S1: Chymotrypsin

Most potent curated ligand interactions (2 total), top 2:

Ligand	Action	Affinity	Parameter
inhibitor 1 [Colombo et al., 2012]	Inhibition	8.08	pKi
compound 5 [PMID: 21741839]	Inhibition	7.72	pKi

ChEMBL bioactivities

56 potent at pChembl≥5 of 62 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.08	Ki	8.4	nM	CHEMBL2086421
7.89	Ki	13	nM	CHEMBL1809213
7.85	Ki	14	nM	CHEMBL1809250
7.82	Ki	15	nM	CHEMBL1809251
7.77	Ki	17	nM	CHEMBL1809238
7.72	Ki	19	nM	CHEMBL1229259
7.66	Ki	22	nM	CHEMBL1809252
7.64	Ki	23	nM	CHEMBL1809253
7.52	Ki	30	nM	CHEMBL1809254
7.47	Ki	34	nM	CHEMBL1809255
7.47	Ki	34	nM	CHEMBL1809256
7.44	Ki	36	nM	CHEMBL1809214
7.42	Ki	38	nM	CHEMBL1809215
7.42	Ki	38	nM	CHEMBL1809239
7.40	Ki	40	nM	CHEMBL1809216
7.37	Ki	43	nM	CHEMBL1809240
7.33	Ki	47	nM	CHEMBL1809257
7.29	Ki	51	nM	CHEMBL1809212
7.28	Ki	53	nM	CHEMBL1809217
7.26	Ki	54.3	nM	CHEMBL1214092
7.24	Ki	57	nM	CHEMBL1809258
7.20	Ki	63	nM	CHEMBL1809218
7.17	Ki	68	nM	CHEMBL1809241
7.14	Ki	73	nM	CHEMBL1809242
7.12	Ki	76	nM	CHEMBL1809219
7.11	Ki	78	nM	CHEMBL252937
7.01	Ki	98	nM	CHEMBL1809220
6.97	Ki	108	nM	CHEMBL1229261
6.95	Ki	112.3	nM	CHEMBL1214093
6.92	Ki	120	nM	CHEMBL1809234
6.87	Ki	135	nM	CHEMBL1809243
6.83	Ki	149	nM	CHEMBL1809244
6.80	Ki	158	nM	CHEMBL1809245
6.78	Ki	168	nM	CHEMBL1809235
6.74	Ki	183	nM	CHEMBL1809246
6.73	IC50	186	nM	CHEMBL5980630
6.70	Ki	202	nM	CHEMBL1809247
6.68	Ki	210	nM	CHEMBL1809248
6.66	Ki	221	nM	CHEMBL1809249
6.53	IC50	297	nM	CHEMBL5980630
6.51	Ki	311	nM	CHEMBL1809236
6.38	Ki	422	nM	CHEMBL1809259
6.37	Ki	430	nM	CHEMBL1809211
6.35	IC50	443	nM	CHEMBL5762635
6.34	IC50	455	nM	CHEMBL5762635
6.34	Ki	457	nM	CHEMBL1809260
6.31	IC50	490	nM	CHEMBL5790408
6.29	Ki	512	nM	CHEMBL1809261
6.27	IC50	542	nM	CHEMBL5790408
5.85	Ki	1425	nM	CHEMBL1809237

PubChem BioAssay actives

44 with measured affinity, of 59 total; 44 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]pentanediamide	682987: Tight binding inhibition of human TMPRSS11D expressed in Drosophila melanogaster S2 cells using Boc-QAR-AMC as substrate incubated for 15 mins prior to substrate addition measured for 30 mins by fluorimetric analysis	ki	0.0084	uM
(2S)-1-[(2R)-2-(benzylsulfonylamino)-6-(diaminomethylideneamino)hexanoyl]-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.0130	uM
4-[[[(5R)-5-(benzylsulfonylamino)-8-(diaminomethylideneamino)-4-oxooctan-3-yl]amino]methyl]benzenecarboximidamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.0140	uM
4-[[[(4S,6R)-6-(benzylsulfonylamino)-9-(diaminomethylideneamino)-5-oxononan-4-yl]amino]methyl]benzenecarboximidamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.0150	uM
(2S)-1-[(2R)-2-(benzylsulfonylamino)-5-oxo-5-(4-pyrimidin-2-ylpiperazin-1-yl)pentanoyl]-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.0170	uM
(2S)-1-[(2R)-2-(benzylsulfonylamino)-5-(diaminomethylideneamino)pentanoyl]-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.0190	uM
4-[[[(3S,5R)-5-(benzylsulfonylamino)-8-(diaminomethylideneamino)-2-methyl-4-oxooctan-3-yl]amino]methyl]benzenecarboximidamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.0220	uM
4-[[[(3S,4S,6R)-6-(benzylsulfonylamino)-9-(diaminomethylideneamino)-3-methyl-5-oxononan-4-yl]amino]methyl]benzenecarboximidamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.0230	uM
4-[[[(2S,4R)-4-(benzylsulfonylamino)-7-(diaminomethylideneamino)-3-oxoheptan-2-yl]amino]methyl]benzenecarboximidamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.0300	uM
benzyl N-[(5S,7R)-7-(benzylsulfonylamino)-5-[(4-carbamimidoylphenyl)methylamino]-10-(diaminomethylideneamino)-6-oxodecyl]carbamate	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.0340	uM
4-[[[(2S,4R)-4-(benzylsulfonylamino)-7-(diaminomethylideneamino)-1-hydroxy-3-oxoheptan-2-yl]amino]methyl]benzenecarboximidamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.0340	uM
tert-butyl (4R)-4-(benzylsulfonylamino)-5-[(2S)-2-[(4-carbamimidoylphenyl)methylcarbamoyl]pyrrolidin-1-yl]-5-oxopentanoate	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.0360	uM
tert-butyl (3R)-3-(benzylsulfonylamino)-4-[(2S)-2-[(4-carbamimidoylphenyl)methylcarbamoyl]pyrrolidin-1-yl]-4-oxobutanoate	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.0380	uM
benzyl 4-[(4R)-4-(benzylsulfonylamino)-5-[(2S)-2-[(4-carbamimidoylphenyl)methylcarbamoyl]pyrrolidin-1-yl]-5-oxopentanoyl]piperazine-1-carboxylate	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.0380	uM
(2S)-1-[(2R)-6-amino-2-(benzylsulfonylamino)hexanoyl]-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.0400	uM
(2S)-1-[(2R)-2-(benzylsulfonylamino)-4-oxo-4-(4-pyrimidin-2-ylpiperazin-1-yl)butanoyl]-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.0430	uM
4-[[[(4S,6R)-6-(benzylsulfonylamino)-9-(diaminomethylideneamino)-2-methyl-5-oxononan-4-yl]amino]methyl]benzenecarboximidamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.0470	uM
benzyl N-[(5S)-5-[[(2R)-2-(benzylsulfonylamino)-3-hydroxypropanoyl]amino]-6-[(4-carbamimidoylphenyl)methylamino]-6-oxohexyl]carbamate	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.0510	uM
benzyl N-[(5R)-5-(benzylsulfonylamino)-6-[(2S)-2-[(4-carbamimidoylphenyl)methylcarbamoyl]pyrrolidin-1-yl]-6-oxohexyl]carbamate	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.0530	uM
(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[(2-aminobenzoyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid	497562: Inhibition of human HAT by FRET assay	ki	0.0543	uM
4-[[[(2S,4R)-4-(benzylsulfonylamino)-7-(diaminomethylideneamino)-3-oxo-1-phenylheptan-2-yl]amino]methyl]benzenecarboximidamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.0570	uM
(2S)-1-[(2R)-2-(benzylsulfonylamino)-4-phenylbutanoyl]-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.0630	uM
(2S)-1-[(2R)-2-(benzylsulfonylamino)-5-oxo-5-piperazin-1-ylpentanoyl]-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.0680	uM
(2S)-1-[(2R)-2-(benzylsulfonylamino)-4-[4-(2,5-dimethylphenyl)piperazin-1-yl]-4-oxobutanoyl]-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.0730	uM
(2S)-1-[(2R)-2-(benzylsulfonylamino)-3-methylbutanoyl]-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.0760	uM
(2S)-2-[[(2R)-2-(benzylsulfonylamino)-3-hydroxypropanoyl]amino]-N-[(4-carbamimidoylphenyl)methyl]-3-hydroxypropanamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.0780	uM
(2S)-1-[(2R)-2-(benzylsulfonylamino)-3-phenylpropanoyl]-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.0980	uM
(2S)-1-[(2R)-2-(benzylsulfonylamino)-3-cyclohexylpropanoyl]-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.1080	uM
(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[(2-aminobenzoyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]hexanoic acid	497562: Inhibition of human HAT by FRET assay	ki	0.1123	uM
(2S)-1-[(2R)-2-(benzylsulfonylamino)-4-methylpentanoyl]-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.1200	uM
benzyl 4-[(3R)-3-(benzylsulfonylamino)-4-[(2S)-2-[(4-carbamimidoylphenyl)methylcarbamoyl]pyrrolidin-1-yl]-4-oxobutanoyl]piperazine-1-carboxylate	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.1350	uM
(2S)-1-[(2R)-2-(benzylsulfonylamino)-4-[4-[3-(dimethylamino)propyl]piperazin-1-yl]-4-oxobutanoyl]-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.1490	uM
(2S)-1-[(2R)-4-(4-benzylpiperazin-1-yl)-2-(benzylsulfonylamino)-4-oxobutanoyl]-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.1580	uM
(2S)-1-[(2R)-2-(benzylsulfonylamino)-3-(4-carbamimidoylphenyl)propanoyl]-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.1680	uM
(2S)-1-[(2R)-2-(benzylsulfonylamino)-4-morpholin-4-yl-4-oxobutanoyl]-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.1830	uM
(2S)-1-[(2R)-2-(benzylsulfonylamino)-4-oxo-4-piperazin-1-ylbutanoyl]-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.2020	uM
(2S)-1-[(2R)-2-(benzylsulfonylamino)-4-[4-(2-hydroxyethyl)piperazin-1-yl]-4-oxobutanoyl]-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.2100	uM
(2S)-1-[(2R)-2-(benzylsulfonylamino)-4-oxo-4-(4-propan-2-ylpiperazin-1-yl)butanoyl]-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.2210	uM
(2S)-1-[(2R)-2-(benzylsulfonylamino)-3-(4-cyanophenyl)propanoyl]-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.3110	uM
(3S,5R)-5-(benzylsulfonylamino)-3-[(4-carbamimidoylphenyl)methylamino]-8-(diaminomethylideneamino)-4-oxooctanoic acid	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.4220	uM
(2R)-2-(benzylsulfonylamino)-N-[2-[(4-carbamimidoylphenyl)methylamino]-2-oxoethyl]-5-(diaminomethylideneamino)pentanamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.4300	uM
4-[[[(4S,6R)-6-(benzylsulfonylamino)-1,9-bis(diaminomethylideneamino)-5-oxononan-4-yl]amino]methyl]benzenecarboximidamide	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.4570	uM
tert-butyl (3S,5R)-5-(benzylsulfonylamino)-3-[(4-carbamimidoylphenyl)methylamino]-8-(diaminomethylideneamino)-4-oxooctanoate	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	0.5120	uM
(3R)-3-(benzylsulfonylamino)-4-[(2S)-2-[(4-carbamimidoylphenyl)methylcarbamoyl]pyrrolidin-1-yl]-4-oxobutanoic acid	610094: Inhibition of human recombinant airway trypsin-like protease HAT using D-cyclohexylalanine-Pro-Arg-AMC as substrate by fluorescence plate reader analysis	ki	1.4250	uM

CTD chemical–gene interactions

13 total (human), top 13 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Asbestos, Crocidolite	decreases methylation, increases expression	2
pirinixic acid	affects binding, decreases expression, increases activity	1
sodium arsenate	decreases expression, increases abundance	1
CGP 52608	affects binding, increases reaction	1
benzylsulfonylargininyl-proline-(4-amidinobenzyl)amide	decreases activity	1
Arsenic	decreases expression, increases abundance	1
Ozone	increases secretion	1
Tetrachlorodibenzodioxin	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Asbestos, Serpentine	decreases methylation	1
Antirheumatic Agents	decreases expression	1
Cadmium Chloride	increases expression	1
Lactic Acid	decreases expression	1

ChEMBL screening assays

10 unique, capped per target: 10 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1219945	Binding	Activity at human HAT by FRET assay	Substrate specificity and inhibitory study of human airway trypsin-like protease. — Bioorg Med Chem

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice